MLS101 Phase 1 study in healthy volunteers

Phase 1, randomised, double-blind trial of psilocybin in Premenstrual Dysphoric Disorder (PMDD), obsessive compulsive disorder (OCD) and opioid use disorder (OUD) (2 arms), sponsored by MycoMedica Life Sciences. Primary endpoints: Incidence, severity, and seriousness of treatment-emergent adverse events and Occurrence of clinically significant changes in physical examination, vital signs, ECGs, clinical laboratory tests, C-SSRS. Started Mar 2024; status: completed.